SNCB and Parkinson disease: Although both proteins are localised at presynaptic terminals and are expressed at similar levels12, 13, β-synuclein has not been implicated in the etiology of Parkinson’s disease but instead has been observed to inhibit the aggregation of α-synuclein both in vitro14, 15 and in vivo16, 17, 18, 19, 20.